Skip to main content
. Author manuscript; available in PMC: 2018 Aug 28.
Published in final edited form as: Cancer Lett. 2017 Jun 7;402:177–189. doi: 10.1016/j.canlet.2017.05.028

Figure 1. Akt1 deficiency blunts oncogenic transformation in TRAMP mouse prostate.

Figure 1

(A) Representative images of 31 week old prostate tissues isolated from TRAMP/Akt1+/+, TRAMP/Akt1+/−, TRAMP/Akt1−/− mice showing significant tumor growth in TRAMP/Akt1+/+prostate, significant reduction in tumor size in TRAMP/Akt1+/−, and no signs of a tumor in TRAMP/Akt1−/− prostate (n=9). (B) Representative images of TRAMP/Akt1+/+, TRAMP/Akt1+/−, TRAMP/Akt1−/− mice prostate tissue sections showing development of PIN in TRAMP/Akt1+/+ mice prostates, and the absence of PIN in TRAMP/Akt1−/− and TRAMP/Akt1+/− mice prostates at 12 weeks of age. Also shown is the presence of high glandular proliferation of the tumor in TRAMP/Akt1+/+ mice prostates, moderate glandular proliferation of the tumor in TRAMP/Akt1+/− mice prostates, and no glandular proliferation of the tumor in TRAMP/Akt1−/− mice prostates at 24 weeks of age (n=6). (C) Bar graphs showing average weight of TRAMP/Akt1+/+, TRAMP/Akt1+/−, TRAMP/Akt1−/− mice prostates at 12, 24 and 31 weeks of age (n=9). Data presented as Mean ± SD; *P < 0.05.